Jan Paeshuyse

Prof. Jan Paeshuyse

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2006 in Hepatology
Verified
Journal Article
Open access
PDF file
JPJan Paeshuyse
Jan Paeshuyse
AKArtur Kaul
Artur Kaul
Erik De ClercqErik De Clercq
Erik De Clercq
BRBrigitte Rosenwirth
Brigitte Rosenwirth
JDJean‐Maurice Dumont
Jean‐Maurice Dumont
JNJohan Hendrik Neyts
Johan Hendrik Neyts
Cyclosporin A (CsA) inhibits the in vitro replication of HCV subgenomic replicons. We here report on the potent anti‐HCV activity of the non‐immunosuppressive cyclosporin DEBIO‐025. The 50% effective concentration for inhibition of HCV subgenomic replicon replication in Huh 5‐2 cells (luciferase assay) by DEBIO‐025 was 0.27 ± 0.03 μg/mL and for CsA 2.8 ± 0.4 μg/mL. The concentration that reduced the growth of exponentially proliferating Huh 5‐2 cells by 50% was greater than 27 μg/mL for DEBIO‐025 and 12 ± 6 μg/mL for CsA, resulting in a selectivity index of approximately 900 for DEBIO‐025 and 40 for CsA. The superior activity of DEBIO‐025, as compared with CsA, was corroborated by monitoring HCV RNA levels in Huh 5‐2, two other HCV subgenomic replicon‐containing cell lines, and by monitoring the luciferase signal and viral antigen production in hepatoma cells that had been infected with an infectious full‐length chimeric HCV construct. The combination of interferon alpha 2a with either CsA or DEBIO‐025 resulted in an additive to slightly synergistic antiviral activity. DEBIO‐025, at concentrations of 0.5 and 1 μg/mL, was able to clear cells from their HCV replicon within three to four passages, whereas treatment with CsA at the same concentrations for seven consecutive passages did not result in clearance of the HCV replicon. In conclusion, DEBIO‐025, a compound that is also endowed with potent anti‐HIV activity and is well tolerated in animals and humans, may form an attractive new option for the therapy of HCV infections, particularly in HCV/HIV co‐infected patients. (HEPATOLOGY 2006;43:761–770.)

27 October 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LCLotte Coelmont
Lotte Coelmont
XHXavier Hanoulle
Xavier Hanoulle
UCUdayan Chatterji
Udayan Chatterji
CBCarola Berger
Carola Berger
JSJoke Snoeck
Joke Snoeck
JNJohan Hendrik Neyts
Johan Hendrik Neyts
DEB025/Debio 025 (Alisporivir) is a cyclophilin (Cyp)-binding molecule with potent anti-hepatitis C virus (HCV) activity both in vitro and in vivo. It is currently being evaluated in phase II clinical trials. DEB025 binds to CypA, a peptidyl-prolyl cis-trans isomerase which is a crucial cofactor for HCV replication. Here we report that it was very difficult to select resistant replicons (genotype 1b) to DEB025, requiring an average of 20 weeks (four independent experiments), compared to the typically <2 weeks with protease or polymerase inhibitors. This indicates a high genetic barrier to resistance for DEB025. Mutation D320E in NS5A was the only mutation consistently selected in the replicon genome. This mutation alone conferred a low-level (3.9-fold) resistance. Replacing the NS5A gene (but not the NS5B gene) from the wild type (WT) genome with the corresponding sequence from the DEB025res replicon resulted in transfer of resistance. Cross-resistance with cyclosporine A (CsA) was observed, whereas NS3 protease and NS5B polymerase inhibitors retained WT-activity against DEB025res replicons. Unlike WT, DEB025res replicon replicated efficiently in CypA knock down cells. However, DEB025 disrupted the interaction between CypA and NS5A regardless of whether the NS5A protein was derived from WT or DEB025res replicon. NMR titration experiments with peptides derived from the WT or the DEB025res domain II of NS5A corroborated this observation in a quantitative manner. Interestingly, comparative NMR studies on two 20-mer NS5A peptides that contain D320 or E320 revealed a shift in population between the major and minor conformers. These data suggest that D320E conferred low-level resistance to DEB025 probably by reducing the need for CypA-dependent isomerisation of NS5A. Prolonged DEB025 treatment and multiple genotypic changes may be necessary to generate significant resistance to DEB025, underlying the high barrier to resistance.

1 March 2009 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
LCLotte Coelmont
Lotte Coelmont
SKSuzanne Kaptein
Suzanne Kaptein
JPJan Paeshuyse
Jan Paeshuyse
IVInge Vliegen
Inge Vliegen
JDJean-Maurice Dumont
Jean-Maurice Dumont
JNJohan Hendrik Neyts
Johan Hendrik Neyts
Debio 025 is a potent inhibitor of hepatitis C virus (HCV) replication (J. Paeshuyse et al., Hepatology 43:761-770, 2006). In phase I clinical studies, monotherapy (a Debio 025 dose of 1,200 mg twice a day) resulted in a mean maximal decrease in the viral load of 3.6 log10units (R. Flisiak et al., Hepatology 47:817-826, 2008), whereas a reduction of 4.6 log10units was obtained in phase II studies when Debio 025 was combined with interferon (R. Flisiak et al., J. Hepatol., 48:S62, 2008). We here report on the particular characteristics of the in vitro anti-HCV activities of Debio 025. The combination of Debio 025 with either ribavirin or specifically targeted antiviral therapy for HCV (STAT-C) inhibitors (NS3 protease or NS5B [nucleoside and nonnucleoside] polymerase inhibitors) resulted in additive antiviral activity in short-term antiviral assays. Debio 025 has the unique ability to clear hepatoma cells from their HCV replicon when it is used alone or in combination with interferon and STAT-C inhibitors. Debio 025, when it was used at concentrations that have been observed in human plasma (0.1 or 0.5 μM), was able to delay or prevent the development of resistance to HCV protease inhibitors as well as to nucleoside and nonnucleoside polymerase inhibitors. Debio 025 forms an attractive drug candidate for the treatment of HCV infections in combination with standard interferon-based treatment and treatments that directly target the HCV polymerase and/or protease.

1 December 2011 in Current Opinion in Virology
Verified
Journal Article
Closed access
JPJan Paeshuyse
Jan Paeshuyse
KDKai Dallmeier
Kai Dallmeier
JNJohan Hendrik Neyts
Johan Hendrik Neyts

1 July 2019 in Computers and Electronics in Agriculture
Verified
Journal Article
Closed access
LCLenn Carpentier
Lenn Carpentier
EVErik Vranken
Erik Vranken
DBDaniel Berckmans
Daniel Berckmans
JPJan Paeshuyse
Jan Paeshuyse
Tomas NortonTomas Norton
Tomas Norton

1 May 2013 in mBio
Verified
Journal Article
Open access
Rob LavigneRob Lavigne
Rob Lavigne
ELElke Lecoutere
Elke Lecoutere
JWJeroen Wagemans
Jeroen Wagemans
WCWilliam Cenens
William Cenens
AAAbram Aertsen
Abram Aertsen
Pieter-Jan CeyssensPieter-Jan Ceyssens
Pieter-Jan Ceyssens
In contrast to the rapidly increasing knowledge on genome content and diversity of bacterial viruses, insights in intracellular phage development and its impact on bacterial physiology are very limited. We present a multifaceted study combining quantitative PCR (qPCR), microarray, RNA-seq, and two-dimensional gel electrophoresis (2D-GE), to obtain a global overview of alterations in DNA, RNA, and protein content in Pseudomonas aeruginosa PAO1 cells upon infection with the strictly lytic phage LUZ19. Viral genome replication occurs in the second half of the phage infection cycle and coincides with degradation of the bacterial genome. At the RNA level, there is a sharp increase in viral mRNAs from 23 to 60% of all transcripts after 5 and 15 min of infection, respectively. Although microarray analysis revealed a complex pattern of bacterial up- and downregulated genes, the accumulation of viral mRNA clearly coincides with a general breakdown of abundant bacterial transcripts. Two-dimensional gel electrophoretic analyses shows no bacterial protein degradation during phage infection, and seven stress-related bacterial proteins appear. Moreover, the two most abundantly expressed early and late-early phage proteins, LUZ19 gene product 13 (Gp13) and Gp21, completely inhibit P. aeruginosa growth when expressed from a single-copy plasmid. Since Gp13 encodes a predicted GNAT acetyltransferase, this observation points at a crucial but yet unexplored level of posttranslational viral control during infection. IMPORTANCE Massive genome sequencing has led to important insights into the enormous genetic diversity of bacterial viruses (bacteriophages). However, for nearly all known phages, information on the impact of the phage infection on host physiology and intracellular phage development is scarce. This aspect of phage research should be revitalized, as phages evolved genes which can shut down or redirect bacterial processes in a very efficient way, which can be exploited towards antibacterial design. In this context, we initiated a study of the human opportunistic pathogen Pseudomonas aeruginosa under attack by one its most common predators, the Phikmvlikevirus . By analyzing various stages of infection at different levels, this study uncovers new features of phage infection, representing a cornerstone for future studies on members of this phage genus.